{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9+%25+sodium+chloride&page=30",
    "query": {
      "intervention": "0.9 % sodium chloride",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 2427,
    "total_pages": 243,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9+%25+sodium+chloride&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9+%25+sodium+chloride&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T13:24:48.216Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04613206",
      "title": "High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunization; Infection",
        "Transplantation Infection",
        "Influenza",
        "Solid Organ Transplant"
      ],
      "interventions": [
        {
          "name": "High Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 396,
      "start_date": "2021-01-11",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04613206"
    },
    {
      "nct_id": "NCT03305055",
      "title": "RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Pain",
        "Wound Care",
        "Posttraumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "ketamine",
          "type": "DRUG"
        },
        {
          "name": "Fentanyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 4,
      "start_date": "2017-12-16",
      "completion_date": "2018-04-21",
      "has_results": true,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03305055"
    },
    {
      "nct_id": "NCT01762852",
      "title": "Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerulonephritis, Membranous"
      ],
      "interventions": [
        {
          "name": "Belimumab 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-04",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2017-03-22",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01762852"
    },
    {
      "nct_id": "NCT04011709",
      "title": "A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cough",
        "Wheezing"
      ],
      "interventions": [
        {
          "name": "VR647 Inhalation System + VR647 Smart Card 3 Secs",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "VR647 Inhalation System + VR647 Smart Card 2 Secs",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "VR647 Inhalation System + VR647 Smart Card 4 Secs",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Vectura Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "1 Year to 5 Years"
      },
      "enrollment_count": 41,
      "start_date": "2017-11-03",
      "completion_date": "2018-02-20",
      "has_results": false,
      "last_update_posted_date": "2019-07-08",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 5,
      "location_summary": "Mission Viejo, California • Plymouth, Minnesota • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04011709"
    },
    {
      "nct_id": "NCT04153149",
      "title": "HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Vutrisiran",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 655,
      "start_date": "2019-11-26",
      "completion_date": "2026-12-02",
      "has_results": true,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 17,
      "location_summary": "La Mesa, California • Los Angeles, California • Stanford, California + 13 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04153149"
    },
    {
      "nct_id": "NCT01188564",
      "title": "Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "rhC1INH",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2011-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2015-08-07",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188564"
    },
    {
      "nct_id": "NCT02481674",
      "title": "A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "VX15/2503",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vaccinex Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 301,
      "start_date": "2015-07",
      "completion_date": "2020-08",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02481674"
    },
    {
      "nct_id": "NCT00862459",
      "title": "Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Diseases",
        "Spinal Cord Diseases"
      ],
      "interventions": [
        {
          "name": "Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)",
          "type": "DRUG"
        },
        {
          "name": "Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)",
          "type": "DRUG"
        },
        {
          "name": "Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)",
          "type": "DRUG"
        },
        {
          "name": "OptiMARK~0.1 mmol/kg BW",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 237,
      "start_date": "2005-08",
      "completion_date": "2007-03",
      "has_results": true,
      "last_update_posted_date": "2014-01-13",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 20,
      "location_summary": "Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00862459"
    },
    {
      "nct_id": "NCT00820846",
      "title": "Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "pGA2/JS7 DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA/HIV62 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 299,
      "start_date": "2009-01",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2022-08-09",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00820846"
    },
    {
      "nct_id": "NCT02028403",
      "title": "Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "BMS-936559",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BMS-936559",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2014-06",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-10-16T13:24:48.216Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02028403"
    }
  ]
}